Immunic shares are trading higher after the company announced the outcome of the interim futility analysis results from its Phase 3 ENSURE program for Vidofludimus Calcium in relapsing multiple sclerosis, with the Data Monitoring Committee recommending to continue trials as planned.
Portfolio Pulse from Benzinga Newsdesk
Immunic's shares rose following positive interim futility analysis results from its Phase 3 ENSURE program for Vidofludimus Calcium in treating relapsing multiple sclerosis. The Data Monitoring Committee recommended continuing the trials as planned.
October 22, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunic's stock price increased due to positive interim results from its Phase 3 ENSURE program for Vidofludimus Calcium, with the Data Monitoring Committee recommending the continuation of trials.
The positive interim results and the recommendation to continue trials are significant milestones for Immunic, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100